Top 5 Stock Picks of Henrik Rhenman’s Rhenman Partners

Page 5 of 5

1. Eli Lilly and Company (NYSE:LLY)

Rhenman Partners’ Stake Value:  $35,367 ,000

Percentage of Rhenman Partners’ 13F Portfolio: 3.48%

Number of Hedge Fund Holders: 53

Eli Lilly and Company (NYSE:LLY) discovers, develops, and sells human pharmaceuticals worldwide.

Rhenman Partners purchased 123,500 shares of Eli Lilly and Company (NYSE:LLY) in Q1 2022, worth $35.3 million, representing 3.48% of the total 13F portfolio.

Eli Lilly and Company (NYSE:LLY) was discussed in the Q1 2022 investor letter of Baron Funds. Here’s what the firm said:

“Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company with a diverse offering primarily focused on therapeutics. Performance was strong mostly due to consistent financial growth powered by its core diabetes (and future obesity) franchise, as well as the constant drumbeat surrounding the Alzheimer’s therapeutic market, of which Eli Lilly has one of the three potential winning blockbuster candidates in Donanemab. We retain conviction in Eli Lilly given the company’s strong long-term growth outlook.”

You can also look at Top 10 Stock Picks of Minerva Advisors and Top 10 Marijuana Stocks to Invest In Right Now.

Page 5 of 5